Accessibility: Skip TopNav
BPGbio Updates Phase 2 Glioblastoma Data at ESMO 2026
BPGbio Presents Phase 2 Glioblastoma Data Update at ESMO Congress 2026, Highlighting Median Overall Survival of 19.9 Months in MGMT-Unmethylated Patients
Format
PNG
Source
BPGbio
Téléchargements
Original
Grand
Moyen
Petit